Information

Related Research Units

Pathology Research
Chiarle Laboratory Research

Research Overview

Visit the Chiarle Laboratory

My laboratory is interested in mechanisms and therapy of cancers. One main focus of the lab is to elucidate the mechanisms that drive transformation of lymphocytes. Most lymphomas, but also an increasing number of solid tumors, are characterized by defined oncogenic events, such as chromosomal translocations. One line of research in the lab is dedicated to the elucidation of basic principles that govern chromosomal translocation formation in normal and neoplastic cells. In collaboration with other groups, we developed a method to map translocations at a genome-wide level, thus initiating a series of studies aimed at defining general rules for translocation formation, focusing on how transcription, DNA Double Strand Breaks (DBSs), tissue specificity and other nuclear or DNA repair factors can influence the type and the frequency of translocations found in human cancers. Among disease-defining translocation in lymphoma, the translocations involving the Anaplastic Lymphoma Kinase (ALK) gene are characteristic of Anaplastic Large Cell Lymphoma (ALCL), but were recently found also in Non-Small Cell Lung Cancers (NSCLC) and other type of solid tumors.

We have extensively studied the role of ALK in lymphoma by discovering multiple pathways exploited to induce cellular transformation. By exploiting xenografts and mouse models for ALCL and NSCLC, and also neuroblastoma, we want to define relevant mechanisms of ALK-mediated transformation in vivo but also to validate therapeutic approaches to target ALK in such cancers. We are currently implementing innovative therapies such as ALK inhibitors, ALK-targeted siRNA and ALK-specific cancer immunotherapy. In this context, we developed a vaccination protocol that generates a strong ALK-specific immunization and seek to explore its potential use in clinical protocols. One more line of research in the lab is devoted to the discovery of novel genetic lesions in lymphoma and solid tumors, by modern techniques of next-generation sequencing. In particular, we recently co-discovered mutations in FBXO11, a gene involved in the degradation of BCL6 in human lymphomas. We aim at expanding these findings to other lymphomas or solid tumors, and at generating mouse models to uncover the role of such gene in normal B cell development and lymphoma formation.

Research Background

Roberto Chiarle received an M.D. degree from the University of Turin, Italy. Then, he earned a Board in Surgical Pathology from the University of Torino. He did his postdoc research training with Giorgio Inghirami and Michele Pagano at the New York University, where he worked on the molecular pathogenesis of B and T cell lymphomas. He was appointed as Assistant Professor in Pathology and as Attending Physician in Pathology in the University of Turin, Italy in 1999, then promoted to Associate Professor in 2006. In Italy, he started his own lab and worked on the ALK oncogene in human lymphoma, to discover new molecular mechanisms of ALK mediated cell transformation and new ALK specific therapies. From 2008 to 2010, he was Visiting Professor in Pathology in Fred W. Alt lab at the Immune Disease Institute/Children’s Hospital, Boston, where he worked on chromosomal translocations and contributed to develop a new high-throughput method to clone translocations genome-wide from primary B cells. In 2012, he was appointed as Associate Professor of Pathology at Harvard Medical School and started his own lab at the Children’s Hospital Boston. He won numerous grants and awards in Europe, such as the Italian National “Premio Sapio” Junior Investigator Award, the Italian National prize “Carlo Chianello” Foundation Research Award, the prestigious ERC Starting Grant from the European Research Council and the research award from the Association for International Cancer Research, UK.

 

Education

Medical School

University of Torino Medical School
1993 Torino Italy

Residency

Anatomic Pathology University of Torino Medical School
1997 Torino Italy

Fellowship

Hematology and Molecular Pathology New York University Medical Center
2001 New York NY

Publications

  1. Endogenous CD4 T cells that recognize ALK and the NPM1::ALK fusion protein can be expanded from human peripheral blood. Cancer Immunol Res. 2025 Jan 07. View Abstract
  2. HSP and CD279 gene expression as candidate biomarkers in symptomatic LGLL patients. Discov Oncol. 2024 Dec 18; 15(1):764. View Abstract
  3. Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma. Br J Cancer. 2024 Dec; 131(11):1781-1795. View Abstract
  4. Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance. Leukemia. 2025 Jan; 39(1):189-198. View Abstract
  5. Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells. bioRxiv. 2024 Oct 01. View Abstract
  6. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024 Oct; 25(10):1298-1309. View Abstract
  7. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers. Nat Commun. 2024 Jun 14; 15(1):5110. View Abstract
  8. Impact of ALK inhibitors to potentiate ALK.CAR-T therapy in neuroblastoma. Clin Transl Med. 2024 Jun; 14(6):e1732. View Abstract
  9. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024 04 04; 143(14):1399-1413. View Abstract
  10. Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T-lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia. Pediatr Blood Cancer. 2024 Jun; 71(6):e30978. View Abstract
  11. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers. Res Sq. 2024 Jan 17. View Abstract
  12. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell. 2023 12 11; 41(12):2100-2116.e10. View Abstract
  13. SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment. Cancer Discov. 2023 11 01; 13(11):2339-2355. View Abstract
  14. Exploiting signaling rewiring in cancer cells with co-existing oncogenic drivers. Mol Oncol. 2023 Nov; 17(11):2215-2217. View Abstract
  15. Correction: The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. J Cell Sci. 2023 Oct 15; 136(20). View Abstract
  16. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia. J Cell Mol Med. 2023 10; 27(20):3053-3064. View Abstract
  17. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat Cancer. 2023 07; 4(7):1016-1035. View Abstract
  18. Targeting CCR7-PI3K? overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. Sci Transl Med. 2023 06 28; 15(702):eabo3826. View Abstract
  19. ERa-associated translocations underlie oncogene amplifications in breast cancer. Nature. 2023 Jun; 618(7967):1024-1032. View Abstract
  20. A five-gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia. Hematol Oncol. 2023 10; 41(4):789-791. View Abstract
  21. DNA repair mechanisms that promote insertion-deletion events during immunoglobulin gene diversification. Sci Immunol. 2023 03 31; 8(81):eade1167. View Abstract
  22. A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas. Blood Adv. 2023 02 14; 7(3):314-316. View Abstract
  23. Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. Nat Commun. 2023 01 13; 14(1):212. View Abstract
  24. Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma. Front Oncol. 2022; 12:1085672. View Abstract
  25. Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases. JTO Clin Res Rep. 2022 Dec; 3(12):100435. View Abstract
  26. Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood. 2022 10 20; 140(16):1822-1826. View Abstract
  27. Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nat Commun. 2022 09 24; 13(1):5614. View Abstract
  28. Choroid plexus-CSF-targeted antioxidant therapy protects the brain from toxicity of cancer chemotherapy. Neuron. 2022 10 19; 110(20):3288-3301.e8. View Abstract
  29. Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites. Nat Commun. 2022 06 27; 13(1):3685. View Abstract
  30. Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. Blood Adv. 2022 05 10; 6(9):2893-2896. View Abstract
  31. Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1. Blood. 2022 04 21; 139(16):2534-2546. View Abstract
  32. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2022 02 03; 139(5):717-731. View Abstract
  33. Deletion of murine Rhoh leads to de-repression of Bcl-6 via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma. Small GTPases. 2022 01; 13(1):267-281. View Abstract
  34. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Adv. 2021 12 14; 5(23):5239-5257. View Abstract
  35. Solving the chromosome puzzle of aneuploidy in cancer. Genes Dev. 2021 08 01; 35(15-16):1073-1075. View Abstract
  36. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Proc Natl Acad Sci U S A. 2021 02 09; 118(6). View Abstract
  37. Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell Stem Cell. 2021 05 06; 28(5):833-845.e5. View Abstract
  38. Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. Mayo Clin Proc. 2021 03; 96(3):817. View Abstract
  39. A LIBRETTO to orchestrate targeted therapy. Nat Cancer. 2020 11; 1(11):1038-1040. View Abstract
  40. High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells. Cancers (Basel). 2020 Oct 13; 12(10). View Abstract
  41. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. Blood. 2020 10 01; 136(14):1657-1669. View Abstract
  42. Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. Lung Cancer. 2020 08; 146:366-369. View Abstract
  43. CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation. Cell Rep. 2019 07 30; 28(5):1307-1322.e8. View Abstract
  44. RHO Family GTPases in the Biology of Lymphoma. Cells. 2019 06 26; 8(7). View Abstract
  45. Comment on "ALK is a therapeutic target for lethal sepsis". Sci Transl Med. 2018 12 12; 10(471). View Abstract
  46. Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nat Med. 2019 01; 25(1):130-140. View Abstract
  47. Parp3 promotes long-range end joining in murine cells. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):10076-10081. View Abstract
  48. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers (Basel). 2018 Feb 28; 10(3). View Abstract
  49. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018 02 08; 172(4):857-868.e15. View Abstract
  50. The CRISPR/Cas9 System as a Tool to Engineer Chromosomal Translocation In Vivo. Adv Exp Med Biol. 2018; 1044:39-48. View Abstract
  51. Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2a Scaffolding Function. Cancer Cell. 2017 10 09; 32(4):444-459.e7. View Abstract
  52. Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget. 2017 Nov 03; 8(54):92265-92274. View Abstract
  53. Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. Clin Immunol. 2017 10; 183:142-144. View Abstract
  54. A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature. 2017 08 10; 548(7666):239-243. View Abstract
  55. Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. Vaccines (Basel). 2017 Aug 01; 5(3). View Abstract
  56. Developmentally-faithful and effective human erythropoiesis in immunodeficient and Kit mutant mice. Am J Hematol. 2017 Sep; 92(9):E513-E519. View Abstract
  57. Primary Cutaneous B-Cell Lymphoblastic Lymphoma Arising from a Long-Standing Lesion in a Child and Review of the Literature. Pediatr Dermatol. 2017 Jul; 34(4):e182-e186. View Abstract
  58. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. Oncotarget. 2017 Mar 21; 8(12):18680-18698. View Abstract
  59. Phosphatidylinositol 3-kinase d blockade increases genomic instability in B cells. Nature. 2017 02 23; 542(7642):489-493. View Abstract
  60. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget. 2017 Jan 10; 8(2):3274-3288. View Abstract
  61. Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms. Proc Natl Acad Sci U S A. 2017 01 17; 114(3):E327-E336. View Abstract
  62. Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. Cancer Res. 2016 10 15; 76(20):6095-6106. View Abstract
  63. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. Oncotarget. 2016 May 31; 7(22):33316-30. View Abstract
  64. Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. Elife. 2016 Mar 17; 5. View Abstract
  65. Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nat Commun. 2016 Mar 09; 7:10934. View Abstract
  66. Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016 Feb; 21(114):125-33. View Abstract
  67. Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. Blood. 2016 Mar 10; 127(10):1297-306. View Abstract
  68. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene. 2016 07 21; 35(29):3854-3865. View Abstract
  69. Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunol Res. 2015 Dec; 3(12):1333-1343. View Abstract
  70. The anaplastic lymphoma kinase as an oncogene in solid tumors. Front Biosci (Schol Ed). 2015 06 01; 7(2):269-82. View Abstract
  71. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015 Apr 09; 161(2):319-32. View Abstract
  72. A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment. Nanomedicine. 2015 Apr; 11(3):741-50. View Abstract
  73. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 2014 Nov 20; 9(4):1219-27. View Abstract
  74. Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. Blood Cancer J. 2014 Oct 10; 4:e249. View Abstract
  75. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res. 2014 Nov 01; 74(21):5978-88. View Abstract
  76. STAT3ß controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. Am J Cancer Res. 2014; 4(5):484-94. View Abstract
  77. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. Cancer Res. 2014 Nov 01; 74(21):6094-106. View Abstract
  78. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study. Lung Cancer. 2014 Aug; 85(2):191-6. View Abstract
  79. IgH class switching exploits a general property of two DNA breaks to be joined in cis over long chromosomal distances. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):2644-9. View Abstract
  80. FuseFISH: robust detection of transcribed gene fusions in single cells. Cell Rep. 2014 Jan 16; 6(1):18-23. View Abstract
  81. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J Hematol Oncol. 2013 Sep 06; 6:67. View Abstract
  82. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. Neoplasia. 2013 May; 15(5):511-22. View Abstract
  83. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis. 2013 Apr 08; 2:e43. View Abstract
  84. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat Methods. 2013 Apr; 10(4):361-5. View Abstract
  85. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. EMBO Mol Med. 2013 Apr; 5(4):572-90. View Abstract
  86. Tissue flow cytometry immunophenotyping in the diagnosis and classification of non-Hodgkin's lymphomas: a retrospective evaluation of 1,792 cases. Cytometry B Clin Cytom. 2013 Mar; 84(2):82-95. View Abstract
  87. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology. 2013 May; 144(5):1098-106. View Abstract
  88. Translocations in normal B cells and cancers: insights from new technical approaches. Adv Immunol. 2013; 117:39-71. View Abstract
  89. The battle against ALK resistance: successes and setbacks. Expert Opin Investig Drugs. 2012 Dec; 21(12):1751-4. View Abstract
  90. Calming down T cell acute leukemia. Cancer Cell. 2012 Apr 17; 21(4):449-50. View Abstract
  91. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012 Jan 05; 481(7379):90-3. View Abstract
  92. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell. 2011 Sep 30; 147(1):107-19. View Abstract
  93. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther. 2011 Dec; 19(12):2201-12. View Abstract
  94. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma. 2011 Sep; 52(9):1742-50. View Abstract
  95. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood. 2011 Jun 16; 117(24):6617-26. View Abstract
  96. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther. 2011 Jun; 19(6):1131-40. View Abstract
  97. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu Rev Immunol. 2011; 29:319-50. View Abstract
  98. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS One. 2010 Oct 01; 5(10). View Abstract
  99. Expression of IFN?R2 mutated in a dileucine internalization motif reinstates IFN? signaling and apoptosis in human T lymphocytes. Immunol Lett. 2010 Nov 30; 134(1):17-25. View Abstract
  100. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem. 2010 Aug 20; 285(34):26441-50. View Abstract
  101. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Mol Carcinog. 2010 Feb; 49(2):114-20. View Abstract
  102. MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Dev Cell. 2010 Jan 19; 18(1):77-89. View Abstract
  103. The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. Adv Immunol. 2010; 106:93-133. View Abstract
  104. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol. 2009 Dec; 27(4):161-70. View Abstract
  105. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009 Nov 15; 69(22):8611-9. View Abstract
  106. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother. 2009 Nov-Dec; 32(9):920-31. View Abstract
  107. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer. 2009 Aug 01; 125(3):639-48. View Abstract
  108. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia. 2009 Nov; 23(11):2102-8. View Abstract
  109. Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin. Eur J Immunol. 2009 Apr; 39(4):1136-46. View Abstract
  110. Anaplastic lymphoma kinase: an oncogene for tumor vaccination. J Mol Med (Berl). 2009 Jul; 87(7):669-77. View Abstract
  111. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008 Nov 01; 68(21):8899-907. View Abstract
  112. Heat shock protein expression in diabetic nephropathy. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1817-24. View Abstract
  113. The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood. 2009 Mar 19; 113(12):2776-90. View Abstract
  114. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008 Jun; 14(6):676-80. View Abstract
  115. Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. Front Biosci. 2008 May 01; 13:6501-14. View Abstract
  116. High energy shock waves (HESW) increase paclitaxel efficacy in a syngeneic model of breast cancer. Technol Cancer Res Treat. 2008 Apr; 7(2):117-24. View Abstract
  117. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res. 2008 Apr 01; 14(7):2220-6. View Abstract
  118. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008 Jan; 8(1):11-23. View Abstract
  119. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res. 2007 Oct; 6(10):4025-31. View Abstract
  120. Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma. Proc Natl Acad Sci U S A. 2007 Sep 04; 104(36):14354-9. View Abstract
  121. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol. 2007 Sep; 149(3):504-12. View Abstract
  122. The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. J Cell Sci. 2007 Jun 01; 120(Pt 11):1859-67. View Abstract
  123. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007 May 01; 67(9):4278-86. View Abstract
  124. Conditional activation of MET in differentiated skeletal muscle induces atrophy. J Biol Chem. 2007 Mar 02; 282(9):6812-22. View Abstract
  125. In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood. 2007 Mar 15; 109(6):2496-504. View Abstract
  126. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006 Dec; 116(12):3171-82. View Abstract
  127. Incestuous paternity detected by STR-typing of chorionic villi isolated from archival formalin-fixed paraffin-embedded abortion material using laser microdissection. J Forensic Sci. 2006 Jan; 51(1):90-2. View Abstract
  128. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle. 2005 Sep; 4(9):1131-3. View Abstract
  129. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood. 2006 Jan 15; 107(2):689-97. View Abstract
  130. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005 Dec 01; 106(12):3907-16. View Abstract
  131. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. Am J Clin Pathol. 2005 Aug; 124(2):182-90. View Abstract
  132. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005 Jun; 11(6):623-9. View Abstract
  133. RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. Cancer Gene Ther. 2005 May; 12(5):456-63. View Abstract
  134. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol. 2004 Apr; 5(4):401-9. View Abstract
  135. Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei. Virchows Arch. 2004 Apr; 444(4):350-5. View Abstract
  136. Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J Biol Chem. 2004 Feb 06; 279(6):4136-43. View Abstract
  137. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia. 2003 Nov; 17(11):2238-40. View Abstract
  138. Estrogen receptor alpha is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor-associated lymphoid infiltrates. Am J Pathol. 2003 Oct; 163(4):1313-20. View Abstract
  139. Role of CD30 in the maturation of thymocytes and in the pathogenesis of autoimmune diseases. Pathologica. 2003 Oct; 95(5):229-30. View Abstract
  140. Expression of the CD31 antigen in normal B-cells and non Hodgkin's lymphomas. J Biol Regul Homeost Agents. 2003 Oct-Dec; 17(4):308-15. View Abstract
  141. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol Cell Biol. 2002 Dec; 22(23):8375-87. View Abstract
  142. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003 Mar 01; 101(5):1919-27. View Abstract
  143. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol. 2002 Apr; 160(4):1457-66. View Abstract
  144. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002 Feb 07; 21(7):1038-47. View Abstract
  145. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2515-20. View Abstract
  146. Induction of germinal centers by MMTV encoded superantigen on B cells. Dev Immunol. 2001; 8(3-4):201-11. View Abstract
  147. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001; 3(2):91-4. View Abstract
  148. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. Br J Haematol. 2000 Oct; 111(1):263-71. View Abstract
  149. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem. 2000 Sep 01; 275(35):27110-6. View Abstract
  150. Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa). Oncogene. 2000 May 25; 19(23):2767-73. View Abstract
  151. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000 Jan 15; 95(2):619-26. View Abstract
  152. Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. Am J Pathol. 1999 Aug; 155(2):355-63. View Abstract
  153. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999 Jul 01; 163(1):194-205. View Abstract
  154. CD30 in normal and neoplastic cells. Clin Immunol. 1999 Feb; 90(2):157-64. View Abstract
  155. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. Am J Hematol. 1997 Dec; 56(4):206-13. View Abstract
  156. Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL). Eur J Haematol. 1997 Sep; 59(3):148-54. View Abstract
  157. Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with increased serum level of CA-125. Gynecol Oncol. 1997 Aug; 66(2):320-3. View Abstract
  158. p53 expression and proliferative activity predict survival in non-invasive thymomas. Int J Cancer. 1996 Jun 21; 69(3):180-3. View Abstract
  159. Long-term survival of thymoma patients by histologic pattern and proliferative activity. Am J Surg Pathol. 1995 Aug; 19(8):918-26. View Abstract
  160. Identification of the same HRAS1 mutation in a primary minimally invasive follicular carcinoma of the thyroid gland and its bone metastasis developed 15 years later. Diagn Mol Pathol. 1995 Mar; 4(1):73-4. View Abstract
  161. Argyrophilic nucleolar organizer region counts predict survival in thymoma. Cancer. 1994 Sep 01; 74(5):1568-74. View Abstract

Contact Roberto Chiarle

Print Profile